家族性腹主动脉瘤患者EVAR术后30天死亡率更高
基于前瞻性注册研究ENGAGE中1262例接受EVAR的腹主动脉瘤患者,其中6.8%有家族史。家族性AAA患者30天死亡率(4.7% vs 1.0%,调整HR 5.7)和动脉瘤相关死亡率(5.8% vs 1.3%,调整HR 5.4)均显著更高,但全因死亡率无差异。
要点
- 家族性AAA患者EVAR术后30天死亡率显著高于散发性(4.7% vs 1.0%)。
- 家族性AAA患者动脉瘤相关死亡率也更高(5.8% vs 1.3%)。
- 临床应视家族性AAA患者为EVAR高危并加强术后监护。
核心结论
- 家族性腹主动脉瘤患者EVAR术后30天死亡率和动脉瘤相关死亡率更高。
研究设计与样本
- 前瞻性、行业赞助的临床注册研究ENGAGE,2009至2011年纳入1262例接受EVAR的AAA患者。
- 根据基线临床报告分为家族性和散发性AAA,随访4.4±1.7年。
主要发现
- 家族性AAA患者86例(6.8%),女性比例更高(18.6% vs 9.9%,p=.012)。
- 临床成功率无显著差异(72.1% vs 79.3%,p=.116)。
临床怎么用
- 应将家族性AAA患者视为EVAR术后高危人群,给予额外警惕和更严密监护。
- 未来研究需明确家族史在AAA治疗方式选择(EVAR vs 开放)及术后监测中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the influence of a positive family history for aneurysms on clinical success and mortality after endovascular aneurysm repair (EVAR). METHODS: From 2009 to 2011, 1262 patients with abdominal aortic aneurysms (AAA) treated by EVAR were enrolled in a prospective, industry sponsored clinical registry ENGAGE. Patients were classified into familial and sporadic AAA patients according to baseline clinical reports. Clinical characteristics, aneurysm morphology, and follow-up were registered. The primary endpoint was clinical success after EVAR, a composite of technical success and freedom from the following complications: AAA increase >5 mm, type I and III endoleak, rupture, conversion, secondary procedures, migration, and occlusion. Secondary endpoints were the individual components of clinical success, 30 day mortality, and aneurysm related and all cause mortality. RESULTS: Of the 1262 AAA patients (89.5% male and mean age 73.1 years), 86 patients (6.8%) reported a positive family history and were classified as familial AAA. Duration of follow-up was 4.4 ± 1.7 years. Patients with familial AAA were more often female (18.6% vs. 9.9%, p = .012). No difference was observed in aneurysm morphology. There was no significant difference in clinical success between patients with familial and sporadic AAA (72.1% vs. 79.3%, p=.116). Familial AAA patients had a higher 30 day mortality after EVAR (4.7% vs. 1.0%, adjusted HR 5.7, 1.8-17.9, p = .003) as well as aneurysm related mortality (5.8% vs. 1.3%, adjusted HR 5.4, 1.9-14.9, p = .001), while no difference was observed in all cause mortality (19.8% vs. 24.3%, adjusted HR 0.8, 0.5-1.4, p = .501). CONCLUSIONS: The current study shows a higher 30 day mortality after EVAR in familial AAA patients. Future studies should determine the role of family history in AAA treatment, suitability for endovascular or open repair, and on adaptation of post-operative surveillance. For the time being, patients with familial forms of AAA should be considered at higher risk for EVAR and warrant extra vigilance.
引用
- van de Luijtgaarden KM, Bastos Gonçalves F, Hoeks SE, et al. Higher 30 Day Mortality in Patients with Familial Abdominal Aortic Aneurysm after EVAR. Eur J Vasc Endovasc Surg. 2017. PMID: 28579278. doi:10.1016/j.ejvs.2017.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。